Loading...
Market
Competitor announces similar STK33 contraceptive research by mid-2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from major pharmaceutical companies or industry news
Story
Study Shows Promise for Nonhormonal Reversible Male Contraceptive Targeting STK33 in Mice
May 24, 2024, 10:14 AM
A new study has highlighted the potential of STK33, a protein essential for male fertility in humans and mice, as a target for nonhormonal and reversible male contraceptives. The study, sponsored by Promega and published in Science Magazine, demonstrated the effectiveness of CDD-2807, a tool compound that achieves reversible inhibition of spermatogenesis in mice. An injection that temporarily affects sperm movement has shown promise as a potential male contraceptive. The targeted inhibition of serine/threonine kinase 33 is central to this contraceptive method.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Merck & Co. • 25%
Novartis • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
United States • 33%
European Union • 33%
Canada • 33%
